Real-time Bayesian personalization via a learnable brain tumor growth
  model by Ezhov, Ivan et al.
1Real-time Bayesian personalization via a learnable
brain tumor growth model
Ivan Ezhov*, Tudor Mot*, Suprosanna Shit, Jana Lipkova, Johannes C. Paetzold, Florian Kofler, Fernando
Navarro, Marie Metz, Benedikt Wiestler and Bjoern Menze
Abstract—Modeling of brain tumor dynamics has the potential
to advance therapeutic planning. Current modeling approaches
resort to numerical solvers that simulate the tumor progression
according to a given differential equation. Using highly-efficient
numerical solvers, a single forward simulation takes up to a
few minutes of compute. At the same time, clinical applications
of the tumor modeling often imply solving an inverse problem,
requiring up to tens of thousands forward model evaluations
when used for a Bayesian model personalization via sampling.
This results in a total inference time prohibitively expensive
for clinical translation. Moreover, while recent data-driven
approaches become capable of emulating physics simulation,
they tend to fail in generalizing over the variability of the
boundary conditions imposed by the patient-specific anatomy.
In this paper, we propose a learnable surrogate with anatomy
encoder for simulating tumor growth which maps the biophysical
model parameters directly to simulation outputs, i.e. the local
tumor cell densities. We test the surrogate on Bayesian tumor
model personalization for a cohort of glioma patients. Bayesian
inference using the proposed neural surrogate yields estimates
analogous to those obtained by solving the forward model with
a regular numerical solver. The near real-time computation cost
renders the proposed method suitable for clinical settings. The
code is available at https://github.com/IvanEz/tumor-surrogate.
Index Terms—Bayesian inference, deep learning, glioma, model
personalization, tumor growth
I. INTRODUCTION
S IMULATION of brain tumor progression can providecomplementary information to medical imaging for ra-
diotherapy planning. As shown in [1]–[12], tumor modeling
can be employed to define a personalized radio-treatment area
using biophysical models to estimate the most likely directions
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of tumor cell infiltration instead of solely targeting tumor area
visible on a scan. These methodologies mainly imply solving
an inverse problem: finding the parameters of the biophysical
tumor growth model resulting in a simulation output that best
matches an empirical observation outlining the pathology.
Existing approaches for inverse tumor modeling resort to
deterministic [2], [4], [13] as well as probabilistic Bayesian
[14]–[16] formalisms. All the approaches require multiple
forward simulations to ensure convergence of the parametric
estimation. The number of simulations ranges from several
thousand for approximate methods [5], [14], [16] to tens of
thousands in case of fully Bayesian analysis [3]. The forward
brain tumor models are often based on the reaction-diffusion
equation and are implemented using highly-efficient numerical
solvers. In [15], authors employ the Lattice Boltzmann method
which allows parallelized computing and takes ca. 80 seconds
on a 60 core machine for simulating the pathology growth. In
[3], the forward model is implemented by means of a multi-
resolution adapted grid solver with a simulation time of 1-3
minutes using 2 cores. Despite the computational advances of
the solvers, the minutes of a single forward model evaluation
multiplied by thousands of forward integrations necessary for
the inverse problem can result in weeks of total computing
time. This constrains the testing of more elaborate tumor
models (e.g., considering cell mixtures or multiple competing
patho-physiological processes [17]), and translation of the
personalized radiotherapy planning into clinical practice [1]–
[4].
As recent years showed, speeding up heavy conventional
computation becomes feasible using end-to-end learning meth-
ods. The data-driven methodology has also penetrated the field
of numerical computing. Learnable surrogates were proposed
for various scientific computing tasks in the natural sciences
by exploiting fully-connected [18]–[20], convolutional [21]–
[23], and hybrid [24]–[26] neural architectures. Among them
are two methods that proved capable of learning even a direct
mapping from the space of parameters driving a simulator to
the space of the simulator solutions in a static geometry [22],
[23]. Unfortunately, these promising methods are incapable of
dealing with inference in arbitrary geometries. This limits their
transfer to model personalization that is crucially dependant on
an adaption to the patient specific simulation domain.
The contribution of the paper is the following: we introduce
a learnable method emulating a numerical tumor (glioma)
growth forward solver. To the best of our knowledge, this is the
first network-based approach in the computational pathology
field that maps parameters of the biophysical model directly to
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Fig. 1: Learnable brain tumor model surrogate. The network is composed of two main parts: a) brain anatomy encoder that maps the
anatomy volumes (WM, GM, CSF) to a latent representation, b) brain tumor decoder that takes as an input a 1D vector of the parameters
{D, ρ, T}, concatenated with the latent representation from (a), and maps the resulting tensor to the 3D tumor simulation volume. The
convolutional block is composed of N=4 repetitions of convolutional operation (with kernel size k=3, stride s=1, number of filters m=128)
and ReLu non-linearity.
the simulation outputs while generalizing over the simulation
geometry. We achieve a 400× speed-up comparing to an
advanced numerical solver by employing the tumor model
surrogate with an anatomy encoder that enforces patient-
specific boundary conditions. This enables a fast Bayesian
model personalization that is consistent with the baseline
numerical solver.
II. METHOD
1) Forward tumor model: The simulations that we aim
to emulate are generated by a 3D numerical solver relying
on a special partial-differential equation (PDE), the Fisher-
Kolmogorov equation. The equation describes the evolution
of the pathology by considering diffusion and proliferation of
the tumor cells under the Neumann boundary condition (B.C.):
∂u
∂t
= ∇(D∇u) + ρu(1− u), (1)
∇u · n = 0 B.C. (2)
Here, u is the normalized 3D tumor cell density, D denotes
the diffusion tensor, ρ is the rate of cell proliferation, and
WMCSF GMT1c
Fig. 2: An example of an MRI T1c scan from the dataset and
corresponding segmentations obtained by registering the brain atlas
to patient space.
n is the normal vector to the boundary. We assume the
migration of the tumor cells to occur only in white matter
(WM) and grey matter (GM), considering isotropic diffusion
with D = D · I (where D ∈ {Dw, Dg} is a diffusion
coefficient in white or grey matter, and I is an identity matrix).
Both WM and GM constitute the simulation domain while
cerebrospinal fluid (CSF) and skull determine the patient-
specific boundary. The input to the solver is a set of parameters
θP = {Dw, ρ, x, y, z, T}, where x, y, z define the position of
3the function u at time T = 0, which is initialized as a point
source.
We simulate the tumors in multiple brain anatomies, which
are extracted from medical scans of patients diagnosed with
the tumor.
2) Learnable forward model surrogate with anatomy en-
coder: Our goal is to learn a surrogate that could map param-
eters of the pathology model θP to corresponding simulations
u(θP ). For this, we base our method on [23] which is designed
to do the mapping for fluid simulations in a static spatial do-
main. Different from [23], we need to consider patient-specific
boundary conditions. To this end, we introduce an anatomy
encoder that imposes anatomical boundary conditions, Fig. 1.
The numerical solver’s output u(θP ) has a size of 128 ×
128 × 128 voxels. However, to provide a greater anatomical
variability to the dataset on which we train the surrogate, we
crop all simulated outputs and corresponding brain anatomies
to 64×64×64 volumes, centered at the initialization location
x, y, z. The 64 × 64 × 64 is greater than half the brain size
and tumors bigger than this are incompatible with life.
The architecture of the tumor model surrogate consists of
two main parts:
- Brain anatomy encoder which encodes 3D volumes of
the brain tissues WM, GM, and CSF through a series of
convolutional blocks. The blocks are composed of alternating
convolution operations (with fixed parameters of kernel size
3, stride 1, and the number of maps 128) and a non-linearity
in the form of a linear rectifier. Each block is equipped with
a skip connection linking the input and output of the block
via an element-wise sum. Downsampling between the blocks
is achieved by a convolutional operation with a stride of two.
- Brain tumor decoder that takes as an input a 1D vector of
the parameters {D, ρ, T} alongside with the encoded anatomy.
Note that we do not condition the decoder on the initialization
location x, y, z, since as mentioned above we crop all training
volumes exactly at this location. Thus the network is taught to
reproduce the tumor in the center for any volume. Before being
passed to the decoder, the 1D vector of model parameters
is mapped via a fully connected layer to a tensor of size
8 × 8 × 8 × 3 and is concatenated with the tensor of the
encoded brain anatomy. The resulting tensor is gradually
upsampled through a series of convolutional blocks analogous
to the encoder and nearest-neighbor upsampling (we refer the
reader to [27] for a detailed discussion on why such type of
upsampling is preferred over the deconvolution operation). At
the end of the series, a 4D tensor 64 × 64 × 64 × 128 is
convolved to the output prediction - a 3D tumor simulation
volume (height 64, width 64, depth 64). The decoder design
is adopted from [23], [28].
As a loss function, we compute the error between the
predicted (upred) and simulated (usim) cell concentration
functions under L1 norm separately in the CSF area and the
area of non-zero ground truth simulated tumor (GT):
Ltotal = ‖usim − upred‖GT>01 + ‖usim − upred‖CSF1 (3)
As shown in the ablation analysis (Fig. 11), such loss
definition significantly affects predictions performance in new
patient geometry.
3) Bayesian model personalization: To demonstrate the
applicability of the neural surrogate, we perform Bayesian
tumor growth model personalization substituting the numerical
solver with the learnable one. As calibration data we use two
types of imaging modalities: (a) T1 contrast-enhanced and
FLAIR MRI modalities that allow estimating the morphologi-
cal characteristic of the visible tumor; (b) FET-PET scans that
provide information about tumor metabolic activity.
Analogous to [14], [15], we relate the output of the tumor
growth solver u(θP ) to imaging information via a probabilistic
model,
p(D | u, θ) = p (yT1c | u, θP ) · p (yFLAIR | u, θI) ·
· p (yPET | u, θI) (4)
where image observations D = {yT1c,yFLAIR,yPET } are
assumed to be independent, and θ = {θP , θI} constitute
parameters of the pathology model θP and the probabilistic
imaging model θI . The latter is defined differently according
to the type of modality:
- MRI modalities provide information in the form of binary
tumor segmentations (yT1c,yFLAIR). Thus we assign for each
voxel a discrete label yMi ∈ {0, 1}, M ∈ {T1c, FLAIR}. We
model the probability of observing yT1c,yFLAIR for a given
concentration u(θP ) with Bernoulli distribution,
p
(
yT1c,FLAIR | u, θMI
)
=
∏
i
p
(
yMi | ui, θMI
)
=
=
∏
i
α
yMi
i,M · (1− αi,M )1−y
M
i ,
(5)
where αi,M is the probability of observing tumor-induced
changes defined as a double logistic sigmoid,
αi,M (ui, uc) = 0.5+0.5·sign
(
ui − uMc
)1− e− (ui−uMc )2σ2α

(6)
With this formulation, we postulate that the tumor is not visible
on a scan below the threshold level uMc . The parameter σα is
introduced to take uncertainty in the threshold concentration
uMc into account.
- FET-PET modality (yPET ) provides continuous informa-
tion in each voxel and can be assumed to be proportional to
T1Gd FLAIR Fet-pet
Fig. 3: An illustration of the imaging information used for
Bayesian model calibration: binary segmentations obtained
from T1Gd and FLAIR modalities, and FET-PET signal which
is proportional to the tumor density.
4CSF
Fig. 4: Qualitative convergence plot for the network predic-
tions over training epochs. For all columns the network input
parameters {D, ρ} and the brain anatomy are fixed, whereas
each column has a different value of T from 100 to 1000
days with intervals of 100 days. The images were obtained
by inferring individual 3D volumes (in a single batch) for all
time values and taking a central 2D slice from each volume.
The last rows framed in green correspond to the ground
truth simulation. The CSF delineation constraining the tumor
growth is framed in red.
Fig. 5: Convergence plot of the total loss. The total loss Ltotal
evaluated on a random batch of size 16 from the test set. We
used samples from 10 patients for training and samples from
the remaining 5 patients for test.
the tumor density [3]. In this case we model the likelihood
imaging function by a Gaussian distribution with unknown
constant of proportionality b:
p
(
yPET | u, θMI
)
=
∏
i
p
(
yi | ui, θMI
)
=
∏
i
N (yi − bui, σ2)
(7)
Here, σ models uncertainty in the PET signal, which is
considered to be normalized yPETi ∈ [0, 1].
In total there are eleven parameters (six pathology model
parameters θP = {Dw, ρ, x, y, z, T} and five imaging model
parameters θI = {uT1cc , uFLAIRc , σα, b, σ}) which we infer
from the triplet of medical scans D = {yT1c,yFLAIR,yPET }
using a Markov Chain Monte Carlo (MCMC) sampling algo-
rithm [29].
4) Implementation: The numerical tumor solver used for
obtaining the simulation dataset is a highly parallelized glioma
solver returning a 3D tumor volume on a uniform spatial grid
[3], [30].
The surrogate network is trained using the Adam optimizer
[31] with decay rates β1 = 0.5 and β2 = 0.999 for 30
epochs, which was observed to be sufficient for convergence.
The learning rate is cosine annealed from 10−4 to 10−6
over the training and the batch size is 16. We performed
the experiments on an NVIDIA Quadro P8000 using the
Tensorflow framework.
For Bayesian MCMC inference we use an implementation
of Transitional MCMC from [32] with 2048 samples per
iteration.
III. EXPERIMENTS
1) Data: The patient-specific tumor-free brain anatomies
(WM, GM, CSF) in which we model the tumor were ob-
tained from an MRI dataset of 15 glioblastoma patients by
registration-based approach proposed in [3], [33]. The data
have resolution 256x256x256 with isotropic voxels of 1mm
side-length, but for simulation purposes, the calibration is per-
formed in data downsampled to 128x128x128. The diffusion
coefficient in white matter Dw is considered to be 10 times
greater than in grey matter Dg . The following ranges are
used for random uniform sampling of the model parameters:
Dw ∈ [0.001, 0.08] mm2/day, ρ ∈ [0.001, 0.03] 1/day, and
T ∈ [50, 1000] day with a step size of 50 days. The tumor
location coordinates x, y, and z are sampled within the brain
volumes. Samples that have initial location {x, y, z} within the
CSF do not trigger any tumor growth and were thus discarded.
For samples with initial location closer than 32 pixels to any
of the volume borders, we do extra padding when cropping
to 64x64x64 size. In total, we have a set of 20k parameters-
simulation pairs for training.
2) Training the surrogate: Conventional application of tu-
mor modeling such as model personalization (via solving an
inverse problem) implies estimating the model parameters by
sampling over fixed, physiologically plausible ranges. Thus,
we aim to employ the learnable surrogate which i) possesses
an interpolation capacity for the parameters {D, ρ, T}, and ii)
is capable to extrapolate for simulations in new geometries. To
probe these properties, the test set of 2k samples was formed
to have only the brain anatomies unseen by the network during
training, while the parametric {D, ρ, T} triplets were sampled
from the same ranges as for the training.
a) Quantitative convergence: Fig. 5 shows the conver-
gence of the loss Ltotal for both training and test sets. Fig. 6
demonstrates the distribution of the mean absolute error within
each class of the brain tissues evaluated on the whole test set.
Even though we observe samples with the error in the order
of 10−1, the majority of the distribution lies within the order
of 10−2. In Fig. 7 we depict the histograms of the DICE
score computed between the simulated and predicted tumor
volumes which are thresholded at different levels of the tumor
5(a) WM (b) GM (c) CSF
Fig. 6: Histograms of the mean absolute error ‖upred −usim‖1 computed on the whole validation set within each class of the
brain tissues (WM, GM, CSF).
(a) DICE > 0.2 (b) DICE > 0.4 (c) DICE > 0.8
Fig. 7: Histograms of the DICE score computed on the whole validation set for the tumor volumes upred and usim thresholded
at 0.2, 0.4, and 0.8 values of tumor cell concentration. The means of the distributions are: a) 0.821, b) 0.813, c) 0.815.
cell concentration (such thresholding is exactly the operation
that we perform during the Bayesian inference to relate tumor
concentration with MRI signals, Eq. 6). The distributions are
centered close to the DICE 1.0. The smaller peak at DICE 0.0
is due to the fact that thresholding of some simulations results
in volumes containing a few (up to 5) non-zero voxels, whereas
thresholding of the corresponding network predictions outputs
volumes of all-zero voxels (or vice versa). In our particular
application of the tumor model personalization such volumes
are significantly smaller that the binary MRI segmentation
volumes to which we calibrate the model and thus do not
affect the Bayesian inference outcome.
b) Qualitative convergence: Fig. 4 illustrates visually the
surrogate’s predictions for simulations from the test set. The
predicted distribution of the tumor concentration accurately
emulates the ground truth simulations. The global constraints
imposed by the CSF anatomy (in which the tumor is con-
strained to grow) are well captured by the network. Fig. 8
depicts a comparison between a network prediction and a
simulated ground truth in 3D.
3) Performance speed-up: The computing time for a single
simulation using the numerical solver is on average 120
seconds using an Intel Xeon with 8 CPU cores and 64GB
of RAM. The time required by using the neural solver for
processing a batch of size 8 during inference is equal to
2.4s, i.e. our surrogate is 400 times faster than the numerical
solver per single simulation. Such a speed-up reduces the
computing time for applications such as model personalization
from weeks to minutes.
Fig. 8: 3D comparison between the predicted (right) and
ground truth (left) tumor simulations embedded in the brain
anatomy.
We want to point out that a theoretical comparison between
CPU- and GPU-based computations should be taken with
care for a few reasons. First, the neural surrogate does not
need to do any sequential computations and can batch process
multiple frames, whereas the numerical solver is successively
integrating the PDE equation in time and for a single sample.
Second, the CPU-based solver acts on a grid of dimension
128x128x128 whereas the network predicts the tumor in
a cropped region of interest of 64x64x64 voxels. Finally,
the convolutional layers are very efficiently realized in most
GPU-tailored deep learning frameworks. In this regard, a fair
comparison could imply to contrast the GPU compute with a
CPU cluster containing as many processing units as the GPU.
However, the latter is rarely available for practical applications,
and as our main goal is clinical translation, we compare CPU
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Fig. 9: Results of the Bayesian inference for patients P1-P5. The three upper rows correspond to the imaging modalities used
for tumor model calibration, namely T1c, FLAIR, and PET-FET. The two bottom rows show the simulations of glioma with
model parameters inferred via the Bayesian inference using the numerical solver and proposed neural surrogate.
7and GPU platforms that are widely available. Also, we empha-
size that when both solvers are tested on the application such
as Bayesian personalization, we treat the empirical imaging
data as well as the simulated domain identically keeping the
size and resolution same (even though the network predicts
64x64x64 tumor volumes centered around the initial location
{x, y, z}, they are then embedded in the original 128x128x128
simulation domain for the personalization task).
4) Bayesian model personalization in patient data: We
performed the Bayesian brain tumor model calibration on
preoperative scans of 5 test patients using the proposed neural
surrogate and numerical solver (the max-a-posterior (MAP)
estimates of the tumor density are provided in Tab.1 in
the appendix). Tumor concentrations modeled with the MAP
estimates are shown in Fig. 9. We observe an agreement of
the glioma profiles obtained by the two methods and the
variability of the estimations is within the variability of the
Bayesian calibration. We also note that the learnable surrogate
is trained on a dataset with continuous uniform distribution
of the diffusion coefficient D and the proliferation rate ρ,
whereas the T parameter has a discrete interval. However,
during the model calibration, the time parameter is sampled
from a continuous interval. This implicitly suggests that the
network’s interpolation capacity is sufficient for parametric
inference.
Lastly, even though we tested the surrogate on the simplistic
Fisher-Kolmogorov model, a translation of the method to more
complicated tumor growth descriptions should be straightfor-
ward (through conditioning with additional model parameters)
at no extra inference time cost.
IV. DISCUSSION
Despite the mentioned advantages, we would like to address
the limitations of the proposed method. As depicted in Fig.
7, even though the Dice distributions are peaked close to a
perfect score, there is a room for improvement to reduce the
deviation. As seen in Fig. 4, the anatomy encoder captures
the global constraints imposed by the CSF anatomy (in which
the tumor is constrained to grow). However, conditioning of
the network on the WM and GM maps improves moderately
the performance as compared to training without such con-
ditioning (see Fig. 7 and 10). This is somewhat expected as
the WM and GM geometries affect numerical simulations in
a highly non-linear fashion as compared to the CSF, geometry
of which is preserved pixel-wise in the output tumor volume.
We experimented with several architectural and hyper-
parametric configurations and selected the one providing the
lowest error on the validation set (Fig. 10 and 11 show exam-
ples of the ablation analysis). Given that the space of network
designs is close to infinite, future research could benefit from
using automated methods for identifying an optimal design,
e.g. exploiting neural architecture search analogous to [22].
We do not have a clear answer to whether the mentioned
limitations and resulting approximation errors are acceptable
for clinical translation. As well as we do not know whether
the Bayesian calibration itself under the simplistic Fisher-
Kolmogorov formalism is suitable for the translation (both
require a study on a large cohort of patients, post-surgery
analysis, etc. [1]–[4]). However, we find the proposed method
to be a solid baseline in the search for optimal tumor model
surrogate, which in turn can significantly speed up our search
for a biophysical model descriptive enough for clinical trials.
V. CONCLUSION
We present the first learnable surrogate with anatomy en-
coder for tumor growth modeling that is capable of map-
ping the model parameters to the corresponding simula-
tions while respecting patient-specific anatomy. Our method
achieves close to real-time simulation allowing fast inference
in Bayesian settings. The technique can be readily adopted to
more complicated tumor growth models and similar 4D inverse
modeling tasks.
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9D ρ T x y z σ b uT1cc u
FLAIR
c σα
P1 Numericalsolver 0.08994 0.01550 572.582 0.3098 0.6748 0.2819 0.2177 0.6384 0.7976 0.3718 0.0514
Neural
surrogate 0.08976 0.01657 553.019 0.3071 0.6657 0.2818 0.1702 0.7198 0.7344 0.3364 0.0500
P2 Numericalsolver 0.08920 0.01993 503.146 0.6121 0.6706 0.3411 0.2358 0.7309 0.6502 0.4376 0.0688
Neural
surrogate 0.08945 0.02882 418.631 0.6217 0.6445 0.3316 0.2434 0.6324 0.6316 0.4337 0.0799
P3 Numericalsolver 0.08998 0.01555 572.128 0.4129 0.3544 0.2900 0.2326 0.7023 0.6088 0.3608 0.0735
Neural
surrogate 0.08990 0.02897 418.946 0.4230 0.3678 0.2901 0.2498 0.6561 0.6294 0.3662 0.0772
P4 Numericalsolver 0.08988 0.01372 609.455 0.3293 0.5657 0.2701 0.2496 0.6894 0.6010 0.3802 0.0758
Neural
surrogate 0.08920 0.02085 493.141 0.3578 0.5839 0.2761 0.2469 0.6287 0.6009 0.3358 0.0679
P5 Numericalsolver 0.08938 0.01080 686.923 0.5530 0.6203 0.3147 0.2484 0.6000 0.6023 0.3775 0.0796
Neural
surrogate 0.08360 0.01066 687.841 0.5701 0.6259 0.3276 0.2411 0.7044 0.6098 0.3790 0.0759
TABLE I: MAP estimates of the marginal distribution from the Bayesian calibration on the patient data using the numerical
solver and proposed neural surrogate. The prior ranges are chosen as follows: Dw ∈ [0.001, 0.09] mm2/day, ρ ∈ [0.001, 0.03]
1/day, T ∈ [30, 1000] days, σ ∈ [0.01, 0.25], b ∈ [0.6, 1.02], uT1cc ∈ [0.6, 0.8], uFLAIRc ∈ [0.05, 0.6], and σα ∈ [0.05, 0.08].
(a) DICE > 0.2 (b) DICE > 0.4 (c) DICE > 0.8
Fig. 10: Ablation analysis I. Instead of inputting 3 volumes of different tissue types (WM, GM, CSF) only a single volume
of CSF tissue serves as an input to the network. The figure shows the histograms of the DICE score computed on the whole
validation set for the tumor volumes upred and usim thresholded at 0.2, 0.4, and 0.8 values of tumor cell concentration. The
means of the distributions are: a) 0.798, b) 0.799, c) 0.801.
(a) DICE > 0.2 (b) DICE > 0.4 (c) DICE > 0.8
Fig. 11: Ablation analysis II. Instead of splitting the Ltotal into two terms as in Eq. 3, a standard L1 loss is used for computing
the error in the whole volume. The figure shows the histograms of the DICE score computed on the whole validation set for
the tumor volumes upred and usim thresholded at 0.2, 0.4, and 0.8 values of tumor cell concentration.
